Structure–activity studies on a library of potent calix[4]arene-based PDGF antagonists that inhibit PDGF-stimulated PDGFR tyrosine phosphorylation
作者:Huchen Zhou、De-an Wang、Laura Baldini、Eileen Ennis、Rishi Jain、Adam Carie、Saïd M. Sebti、Andrew D. Hamilton
DOI:10.1039/b515483a
日期:——
Platelet-derived growth factor (PDGF) and its receptor PDGFR are required for tumor growth and angiogenesis, so disruption of the PDGFâPDGFR interaction should lead to starvation of tumors and reduction of tumor growth. Potent PDGF antagonists have been discovered through the synthesis of a series of calix[4]arene-based compounds that are designed to bind to the three-loop region of PDGF. The effect of lower-rim alkylation, linker and number of interacting head groups on the calix[4]arene scaffold on PDGF affinity and cellular activity has been investigated.
The present invention relates to insulin derivatives having a side chain attached either to the -amino group of the N-terminal amino acid residue of the B chain or to the amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.
The present invention relates to insulin derivatives having a side chain attached either to the α-amino group of the N-terminal amino acid residue of the B chain or to the ε-amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds.
[EN] The present invention relates to insulin derivatives having a side chain attached either to the -amino group of the N-terminal amino acid residue of the B chain or to the amino group of a Lys residue present in the B chain of the parent insulin via an amide bond which side chain comprises at least one aromatic group; at least one free carboxylic acid group or a group which is negatively charged at neutral pH, a fatty acid moiety with 4 to 22 carbon atoms in the carbon chain; and possible linkers which link the individual components in the side chain together via amide bonds. [FR] La présente invention concerne des dérivés d'insuline présentant une chaîne latérale fixée soit au groupe a-amino du résidu aminoacide N-terminal de la chaîne B, soit au groupe e-amino d'un résidu lysine présent dans la chaîne B de l'insuline mère par le biais d'une liaison amide, laquelle chaîne latérale comporte au moins un groupe aromatique, au moins un groupe acide carboxylique libre ou un groupe chargé négativement à pH neutre, une partie acide gras, présentant 4 à 22 atomes de carbone dans la chaîne carbonée, et des lieurs éventuels liant les constituants individuels dans la chaîne latérale entre eux par le biais de liaisons amides.